KRAS and adenocarcinoma: Molecular biological analysis of the 93 patients with adenocarcinoma showed 59 epidermal growth factor receptor (EGFR) mutations (63.4%), five KRAS mutations (5.4%) and four EML4-ALK rearrangements (4.3%).